Active clinical trials of the Pediatric Early Clinical Trials East Network.

 

Please find here an overview of our current clincical trial portfolio.

If you are interested in participating in a specific study,

Please do not hesitate to contact us!

Leukemias
Lymphomas
Solid Tumors
ZNS Tumors
Other diseases

Active clinical trials of the Research Network

On this page you will find an overview of our currently active studies. If you are interested in participating in a specific study, please email the contact person at the respective clinics. You will find the contact information via the respective link to the website of the respective study locations.

Please do not hesitate to contact us!

Leukämien
Lymphome
Solid Tumors
ZNS Tumors
Other diseases

Leukemias


Investigational drug: Bosutinib

Indication: newly diagnosed chronic phase or resistant/intolerant Ph+ CML

Phase: I/II

Protocol Nr.: ITCC-054/COG AAML1921

EudraCT/NCT-Nr.: EudraCT2015-002916-34

Trial location: Berlin, Charité

Investigational drug: Cellgene JCAR

Indication: B-ALL + B-NHL

Phase: I/II

Protocol Nr.: JCAR017-BCM-004

EudraCT/NCT-Nr.: EudraCT2018-001246-34

Trial location: Berlin, Charité

Investigational drug: Daratumomab

Indication: ALL

Phase: II

Protocol Nr.: 54767414ALL2005

EudraCT/NCT-Nr.: EudraCT2017-003377-34

Trial location: Berlin, Charité

Investigational drug: Inotuzumab/CD22

Indication: CD22+ relapsed/refractory BCP-ALL

Phase: II

Protocol Nr.: ITTC-059 / NTR5736

EudraCT/NCT-Nr.: EudraCT2016-000227-71

Trial location: Berlin, Charité

Investigational drug: MB-CART19.1

Indication: B-ALL REZ

Phase: II/III

Protocol Nr.: M-2017-322

EudraCT/NCT-Nr.: EudraCT2017‐002848‐32

Trial location: Berlin, Charité

Investigational drug: Midostaurin

Indication: FLT3pos AML

Phase: II

Protocol Nr.: CPKC412A2218

EudraCT/NCT-Nr.: EudraCT2017-004830-28

Trial location: Berlin, Charité

Lymphomas


Investigational drug: Bosutinib

Indication: newly diagnosed chronic phase or resistant/intolerant Ph+ CML

Phase: I/II

Protocol Nr.: ITCC-054/COG AAML1921

EudraCT/NCT-Nr.: EudraCT2015-002916-34

Trial location: Berlin, Charité

Investigational drug: Brigatinib

Indication: ALK+ ALCL, Solid Tumors, IMT

Phase: I/II

Protocol Nr.: ITCC-098 Briga Ped

EudraCT/NCT-Nr.: EudraCT2021-002713-34

Trial location: Berlin, Charité

Investigational drug: Cellgene JCAR

Indication: B-ALL + B-NHL

Phase: I/II

Protocol Nr.: JCAR017-BCM-004

EudraCT/NCT-Nr.: EudraCT2018-001246-34

Trial location: Berlin, Charité

Investigational drug: Pembrolizumab

Indication: Hodgkin Lymphoma

Phase: II

Protocol Nr.: Keynote 667

EudraCT/NCT-Nr.: EudraCT2017-001123-53

Trial location: Berlin, Charité

Solid Tumors


Investigational drug: Abemaciclib

Indication: Relapsed/Refractory Solid Tumors

Phase: I/II

Protocol Nr.: JP04

EudraCT/NCT-Nr.: NCT05440786

Trial location: Berlin, Charité

Investigational drug: Abemaciclib LY2835219

Indication: Relapsed/Refractory Solid Tumors

Phase: Ib

Protocol Nr.: I3Y-MC-JPCS

EudraCT/NCT-Nr.: EudraCT2019-002931-27

Trial location: Berlin, Charité

Investigational drug: Brigatinib

Indication: ALK+ ALCL, Solid Tumors, IMT

Phase: I/II

Protocol Nr.: ITCC-098 Briga Ped

EudraCT/NCT-Nr.: EudraCT2021-002713-34

Trial location: Berlin, Charité

Investigational drug: Dinutuximab beta

Indication: Neuroblastoma, relapsed/refraktory

Phase: I/II

Protocol Nr.: APN311-304

EudraCT/NCT-Nr.: EudraCT2014-000588-42

Trial location: Berlin, Charité

Investigational drug: Larotrectinib

Indication: Solid Tumors

Phase: I/II

Protocol Nr.: SCOUT Bayer (LOXO-TRK-15003G)

EudraCT/NCT-Nr.: EudraCT2016-003498-16

Trial location: Berlin, Charité

Investigational drug: Nivolumab + Entinostat

Indication: Refractory high risk malignoma

Phase: I/II

Protocol Nr.: INFORM2 NivEnt

EudraCT/NCT-Nr.: EudraCT2018-000127-14

Trial location: Berlin, Charité

Investigational drug: Venetoclax

Indication: NHL, Neuroblastoma

Phase: I

Protocol Nr.: M13-838

EudraCT/NCT-Nr.: EudraCT2017-000439-14

Trial location: Berlin, Charité

ZNS Tumors


Investigational drugs: DAY101 FIREFLY-1

Indication: pan RAFi

Phase: I/II

Protocol Nr.: FireFly DAY 101

EudraCT/NCT-Nr.: EudraCT2020-003657-30

Trial location: Berlin, Charité

Investigational drug: Larotrectinib

Indication: Solid Tumors

Phase: I/II

Protocol Nr.: SCOUT Bayer (LOXO-TRK-15003G)

EudraCT/NCT-Nr.: EudraCT2016-003498-16

Trial location: Berlin, Charité

Investigational drug: Selumetinib

Indication: NF1 Related Symptomatic, Inoperable Plexiform Neurofibromas (PN)

Phase: I/II

Protocol Nr.: SPRINKLE D1346C00004

EudraCT/NCT-Nr.: EudraCT2020-005608-20

Trial location: Berlin, Charité

Other deseases


Investigational drug: CDZ173/Leniolisib

Indication: NF1 Related Symptomatic, Inoperable Plexiform Neurofibromas (PN)

Phase: II/III

Protocol Nr.: CCDZ173X2201

EudraCT/NCT-Nr.: EudraCT2016-000468-41

Trial location: Dresden

Investigational drug: Crizanlizumab

Indication: Sickel cell disease

Phase: II

Protocol Nr.: CSEG 101B2201

EudraCT/NCT-Nr.: EudraCT2017-001747-12

Trial location: Berlin, Charité